Natural inflammation‑resolving molecules and emphysema
Role of specialized pro-resolving mediators of inflammation resolution in emphysema: analyses of SPIROMICS and LEEP
This project looks at whether higher blood levels of natural inflammation‑resolving molecules are linked to better breathing and less lung damage in people with emphysema.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11144318 on NIH RePORTER |
What this research studies
If you have emphysema, the team will measure specific blood lipids called specialized pro‑resolving mediators (SPMs) that help the body switch off inflammation. They will use stored blood samples and detailed health data from large COPD research groups (SPIROMICS) and then check the findings in another group (LEEP). The researchers will compare SPM levels with lung function, emphysema severity on scans, and respiratory outcomes to see which patterns relate to better or worse health. Findings will be validated across both datasets to strengthen confidence in any links they find.
Who could benefit from this research
Good fit: Ideal candidates are adults diagnosed with emphysema or COPD, especially those who have provided or would provide blood samples and clinical data to research cohorts.
Not a fit: People without emphysema or COPD or those expecting immediate new treatments should not expect direct personal benefit from this observational research.
Why it matters
Potential benefit: If successful, this work could point to blood markers and new ways to boost the body’s natural inflammation‑resolving pathways to protect lungs in emphysema.
How similar studies have performed: Similar research has linked these inflammation‑resolving molecules to outcomes in asthma, cardiovascular disease, and COVID‑19, but their role in emphysema is largely unproven and novel.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Bose, Sonali — Icahn School of Medicine at Mount Sinai
- Study coordinator: Bose, Sonali
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.